{"id":"jcar017","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neurological events"}]},"_chembl":{"chemblId":"CHEMBL4297236","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"JCAR017 involves genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen found on the surface of B cells, leading to the destruction of CD19-positive cells, including cancerous B cells in certain types of lymphoma.","oneSentence":"JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:57:21.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT03331198","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2017-11-27","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic","enrollment":320},{"nctId":"NCT05873712","phase":"PHASE2","title":"Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome","status":"RECRUITING","sponsor":"Aseel Alsouqi","startDate":"2023-07-28","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT05633615","phase":"PHASE2","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-06-12","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":396},{"nctId":"NCT07098364","phase":"PHASE1, PHASE2","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-27","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":33},{"nctId":"NCT07194980","phase":"PHASE2","title":"Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-04-01","conditions":"Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":20},{"nctId":"NCT05672173","phase":"PHASE2","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-06-02","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":20},{"nctId":"NCT04400591","phase":"","title":"Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol","status":"AVAILABLE","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":""},{"nctId":"NCT04245839","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2020-07-14","conditions":"Lymphoma, Non-Hodgkin","enrollment":276},{"nctId":"NCT03575351","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-23","conditions":"Lymphoma, Non-Hodgkin","enrollment":184},{"nctId":"NCT03744676","phase":"PHASE2","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-11-29","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell","enrollment":104},{"nctId":"NCT03484702","phase":"PHASE2","title":"Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-06-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":113},{"nctId":"NCT03743246","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"TERMINATED","sponsor":"Celgene","startDate":"2018-10-17","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin","enrollment":21},{"nctId":"NCT02631044","phase":"PHASE1","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2016-01-06","conditions":"Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":387},{"nctId":"NCT03310619","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-20","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":62},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT03483103","phase":"PHASE2","title":"Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-07-27","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell","enrollment":74},{"nctId":"NCT03436771","phase":"","title":"Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product","status":"TERMINATED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-02-19","conditions":"Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lisocabtagene Maraleucel (liso-cel)"],"phase":"phase_2","status":"active","brandName":"JCAR017","genericName":"JCAR017","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}